Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.93 |
| ▸ | GLA | P06280 | 1/20 | 0.93 |
| ▸ | KDM1A | O60341 | 5/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | SAT1 | P21673 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899291 | 1.00 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL7871599 | 1.00 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL4157457 | 1.00 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL4171429 | 1.00 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL10045117 | 1.00 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| Bis(Ethyl)Spermine SCHEMBL7092466 | 1.00 | CYP2C19 (1.00) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL2529872 | 0.97 | CYP2C19 (0.93) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL10045203 | 0.97 | CYP2C19 (0.93) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| Bis(Ethyl)Spermine SCHEMBL8526460 | 0.97 | CYP2C19 (0.93) | CYP2C19CYP1A2MEN1KMT2AGLA | |
| SCHEMBL10045209 | 0.97 | CYP2C19 (0.93) | CYP2C19CYP1A2MEN1KMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240309418-A1 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | MASSACHUSETTS GEN HOSPITAL (US) | 2024-09-19 | — | — | US | disclosed |
| EP-3971178-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | The McLean Hospital Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1698629-A2 | Polyamines and their use in therapy | Cellgate, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1177197-B1 | POLYAMINES AND THEIR USE IN THERAPY | CELLGATE INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060160906-A1 | Polyamine analogs as therapeutic agents for ocular diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-07-20 | — | — | US | disclosed |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6794545-B1 | INCREASES IN THE POLYAMINE POOL SUPPRESS POLYAMINE BIOSYNTHESIS ALSO INHIBIT CELL GROWTH; ANTIPROLIFERATIVE AGENT | SLIL BIOMEDICAL CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | SLIL BIOMEDICAL CORPORATION (US) | 2004-01-08 | — | — | US | disclosed |
| US-6649587-B1 | Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B | SLIL BIOMEDICAL CORPORATION | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | CYP2C19 3757/4885CYP1A2 4456/4885MEN1 177/4885 |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | CYP2C19 3757/4885CYP1A2 4456/4885MEN1 177/4885 |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | CYP2C19 2936/4885CYP1A2 3658/4885MEN1 894/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | CYP2C19 4605/4885CYP1A2 4040/4885MEN1 2393/4885 |
| US-20060160906-A1 | Polyamine analogs as therapeutic agents for ocular diseases | SRM, SMS, ARG2 | CYP2C19 3558/4885CYP1A2 4565/4885MEN1 1433/4885 |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | CYP2C19 2936/4885CYP1A2 3658/4885MEN1 894/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | CYP2C19 4541/4885CYP1A2 4823/4885MEN1 401/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | CYP2C19 4252/4885CYP1A2 3593/4885MEN1 2868/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | CYP2C19 4252/4885CYP1A2 3593/4885MEN1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.